Care pathways for reduced fetal movements: A cost-consequence analysis

被引:0
|
作者
Mcknoulty, Matthew J. [1 ]
Martin, Elizabeth K. [2 ]
机构
[1] Univ Queensland, Metro North Hlth, Queensland Hlth, Brisbane, Qld, Australia
[2] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia
关键词
costs and costs analysis; health services research; midwifery; obstetrics; stillbirth;
D O I
10.1111/ajo.13883
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective This study aimed to evaluate the costs and consequences of a new midwife-navigator-facilitated care pathway for reduced fetal movements. Materials and Methods This study was conducted at a tertiary obstetric centre in Queensland, Australia and modelling occurred for this and smaller services. Two months of data from pre (n = 112 in 2019) and post (n = 141 in 2020) implementation of the care pathway were analysed with T-tests and logistic regression models to evaluate maternal and neonatal outcomes. A Markov model was built to estimate the costs and consequences of the intervention. Sensitivity analysis was conducted to test various scenarios including modelling for smaller centres. Results There were no statistically significant differences in clinical outcome between the intervention and usual care groups. Intervention patients spent one hour and eight minutes less time in hospital (P < 0.001). This resulted in a saving to the centre of AU$135 per patient (AU$159 083 annually). One-way sensitivity analysis suggested that cost savings would be found in all scenarios except for smaller units providing services for less than 1900 births per annum. Conclusion(s) To our knowledge, no other care pathway involving acute obstetric care has been economically evaluated to date. Our model based on real-world presentations for reduced fetal movements confirms that midwife-navigators may be an economically beneficial implementation strategy for dealing with common obstetric conditions.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease
    Pengxin Dong
    Hao Hu
    Xiaodong Guan
    Carolina Oi Lam Ung
    Luwen Shi
    Sheng Han
    Shuwen Yu
    [J]. Chinese Medicine, 13
  • [22] OVERVIEW OF COST-CONSEQUENCE MODELING IN OUTCOMES RESEARCH
    STERGACHIS, A
    [J]. PHARMACOTHERAPY, 1995, 15 (05): : S40 - S42
  • [23] COST-CONSEQUENCE ANALYSIS OF CSII VS. MDI: A CANADIAN PERSPECTIVE
    Sadri, H.
    Bereza, B. G.
    Longo, C. J.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [24] Evaluating stroke early supported discharge using cost-consequence analysis
    Byrne, Adrian
    Chouliara, Niki
    Cameron, Trudi
    Geue, Claudia
    Lewis, Sarah
    Robinson, Thompson
    Langhorne, Peter
    Walker, Marion F.
    Fisher, Rebecca J.
    [J]. DISABILITY AND REHABILITATION, 2022, 44 (23) : 7127 - 7133
  • [25] Economic evaluation of computerised interpretation of fetal heart rate during labour: a cost-consequence analysis alongside the INFANT study
    Schroeder, Elizabeth
    Yang, Miaoqing
    Brocklehurst, Peter
    Linsell, Louise
    Rivero-Arias, Oliver
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2021, 106 (02): : F143 - F148
  • [26] COMPARATIVE COST-CONSEQUENCE ANALYSIS OF THE BIVALENT AND QUADRIVALENT VACCINES AGAINST HPV IN SPAIN
    Lopez Belmonte, J. L.
    Cortes Bordoy, J.
    Gil de Miguel, A.
    Bresse, X.
    Serip, S.
    Nieves, D.
    Bosch, X.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A408 - A408
  • [27] Cost-consequence analysis evaluating multifaceted clinical pharmacist intervention targeting patient transitions of care from hospital to primary care
    Rasmussen, Maja Kjaer
    Ravn-Nielsen, Lene Vestergaard
    Duckert, Marie-Louise
    Lund, Mia Lolk
    Henriksen, Jolene Pilegaard
    Nielsen, Michelle Lyndgaard
    Eriksen, Christina Skovsende
    Buck, Thomas Croft
    Hansen, Morten Rix
    Pottegard, Anton
    Hallas, Jesper
    Kidholm, Kristian
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2019, 2 (02): : 123 - 130
  • [28] A cost-consequence analysis of the Queensland specialist palliative rural telehealth (SPaRTa) service
    Snoswell, Centaine L.
    Smith, Anthony C.
    Grove, Graham
    Broadbent, Andrew
    Caffery, Liam J.
    Thomas, Emma
    Kelly, Jaimon
    Haydon, Helen M.
    [J]. PROGRESS IN PALLIATIVE CARE, 2024, 32 (05) : 326 - 333
  • [29] Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
    Seungju Cha
    Minjeong Sohn
    Hyowon Yang
    Eric J. Yeh
    Ki-Hyun Baek
    Jeonghoon Ha
    Hyemin Ku
    [J]. BMC Musculoskeletal Disorders, 25
  • [30] Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis
    Horgan, A. M.
    Knox, J. J.
    Liu, G.
    Sahi, C.
    Bradbury, P. A.
    Leighl, N. B.
    [J]. CURRENT ONCOLOGY, 2011, 18 (02) : E64 - E70